Luisa Lina Villa

Cytowane przez

	Wszystkie	Od 2020
Cytowania	40180	8716
h-indeks	92	45
i10-indeks	362	233

2500

1250

625

1875

19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025136 89 135 161 201 316 341 419 628 1014 1628 1937 2015 2043 2173 2289 2406 2292 2150 2117 1982 1883 1835 1898 1894 1650 1580 1509 179

Dostęp publiczny

Wyświetl wszystko

141 artykułów

2 artykuły

dostępne

niedostępne

Objęte finansowaniem

Współautorzy

Dr. Jorge SalmerónCentro de Investigación en Políticas, Población y Salud. Facultad de Medicina, UNAMZweryfikowany adres z unam.mx
Enrique BoccardoProfessor of Virology, Institute of Biomedical Sciences, University of São PauloZweryfikowany adres z usp.br
Lara TerminiScientific Researcher - ICESP - Faculdade de Medicina da USPZweryfikowany adres z hc.fm.usp.br
Ana Paula LepiqueUniversidade de São PauloZweryfikowany adres z icb.usp.br
Trottier HelenUniversité de Montréal / Sainte-Justine HospitalZweryfikowany adres z umontreal.ca
Luiz Carlos ZeferinoProf Titular em Ginecologia, Fac Ciências Médicas. Diretor da Divisão de Oncologia do CAISM, UNICAMPZweryfikowany adres z fcm.unicamp.br
José Humberto Tavares Guerreiro Fre...A. C. Camargo Cancer CenterZweryfikowany adres z accamargo.org.br
Silvia Helena Rabelo-SantosProfessora de Citologia Clínica, Faculdade de Farmácia, Universidade Federal de GoiásZweryfikowany adres z ufg.br
Christine M. PierceMerck & Co., Inc.Zweryfikowany adres z merck.com
Sophie DerchainProfessor of Gynecology, State University of CampinasZweryfikowany adres z pq.cnpq.br
Itzel E Calleja-MaciasVanguard UniversityZweryfikowany adres z vanguard.edu
Tatiana RabachiniUniversity of Bern - SwitzerlandZweryfikowany adres z pki.unibe.ch
Salaheddin MahmudProfessor and Canada Research Chair of Pharmaco-epidemiology, University of ManitobaZweryfikowany adres z mcgill.ca
Matthew B. Schabath, Ph.D.H. Lee Moffitt Cancer Center & Research InstituteZweryfikowany adres z moffitt.org
Silvya Stuchi Maria-EnglerFull Professor of School of Pharmaceutical Sciences, University of São PauloZweryfikowany adres z usp.br
Mark SchiffmanNational Cancer InstituteZweryfikowany adres z mail.nih.gov
John T. SchillerNational Caner Institute, NIHZweryfikowany adres z mail.nih.gov
Luciana Yuki TomitaFederal University of Sao PauloZweryfikowany adres z unifesp.br
Marly Augusto CardosoDepartamento de Nutrição, Faculdade de Saúde Pública, Universidade de São PauloZweryfikowany adres z usp.br
Suely NonogakiPesquisador científico do Instituto Adolfo LutzZweryfikowany adres z ial.sp.gov.br

Obserwuj

Luisa Lina Villa

Professora de Oncologia Básica, Depto Radiologia da Faculdade de Medicina da Universidade de São

Zweryfikowany adres z hc.fm.usp.br

câncer epidemiologia biologia molecular papilomavírus humano


Tytuł Sortuj wg cytatów Sortuj wg roku Sortuj wg tytułu	Cytowane przez Cytowane przez	Rok
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions Future II Study Group New England Journal of Medicine 356 (19), 1915-1927, 2007	2492	2007
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre … LL Villa, RLR Costa, CA Petta, RP Andrade, KA Ault, AR Giuliano, ... The lancet oncology 6 (5), 271-278, 2005	2390	2005
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer EL Franco, LL Villa, JP Sobrinho, JM Prado, MC Rousseau, M Désy, ... The Journal of infectious diseases 180 (5), 1415-1423, 1999	998	1999
Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia NF Schlecht, S Kulaga, J Robitaille, S Ferreira, M Santos, RA Miyamura, ... Jama 286 (24), 3106-3114, 2001	886	2001
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a … KA Ault The Lancet 369 (9576), 1861-1868, 2007	877	2007
HPV type-distribution in women with and without cervical neoplastic diseases G Clifford, S Franceschi, M Diaz, N Muñoz, LL Villa Vaccine 24, S26-S34, 2006	838	2006
Updating the natural history of HPV and anogenital cancer AB Moscicki, M Schiffman, S Kjaer, LL Villa Vaccine 24, S42-S51, 2006	799	2006
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up LL Villa, RLR Costa, CA Petta, RP Andrade, J Paavonen, OE Iversen, ... British Journal of Cancer 95 (11), 1459-1466, 2006	737	2006
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in … DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... The Journal of infectious diseases 199 (7), 926-935, 2009	710	2009
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 LL Villa, KA Ault, AR Giuliano, RLR Costa, CA Petta, RP Andrade, ... Vaccine 24 (27-28), 5571-5583, 2006	687	2006
Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013	659	2013
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide … HU Bernard, SY Chan, MM Manos, CK Ong, LL Villa, H Delius, CL Peyton, ... Journal of Infectious Diseases 170 (5), 1077-1085, 1994	639	1994
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study AR Giuliano, JH Lee, W Fulp, LL Villa, E Lazcano, MR Papenfuss, ... The Lancet 377 (9769), 932-940, 2011	620	2011
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts … Future I/II Study Group The BMJ 341, 2010	556	2010
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women N Muñoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... Journal of the National Cancer Institute 102 (5), 325-339, 2010	485	2010
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia NF Schlecht, RW Platt, E Duarte-Franco, MC Costa, JP Sobrinho, ... Journal of the National Cancer Institute 95 (17), 1336-1343, 2003	465	2003
Human papillomavirus infections with multiple types and risk of cervical neoplasia H Trottier, S Mahmud, MC Costa, JP Sobrinho, E Duarte-Franco, ... Cancer Epidemiology Biomarkers & Prevention 15 (7), 1274-1280, 2006	461	2006
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States AR Giuliano, E Lazcano-Ponce, LL Villa, R Flores, J Salmeron, JH Lee, ... Cancer Epidemiology Biomarkers & Prevention 17 (8), 2036-2043, 2008	457	2008
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results JT Schiller, X Castellsagué, LL Villa, A Hildesheim Vaccine 26, K53-K61, 2008	427	2008
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, ... Cancer prevention research 2 (10), 868-878, 2009	419	2009

Nie można teraz wykonać tej operacji. Spróbuj ponownie później.

Prace 1–20

Cytowania rocznie

Powielone cytowania

Scalone cytowania

Dodaj współautorówWspółautorzy

Obserwuj

Cytowane przez

Współautorzy